 Once a highly speculative, non-revenue generating biotech on the verge of bankruptcy MNKD has de-risked much of the previous market concerns over bankruptcy, debt and credit issues. Their flagship product sold under the brand name AFREZZA is the only FDA approved rapid acting, dry powder inhalation formula for meal time glucose management. 